RxDoctor Payments Data

Jessica Hopper

Nurse Practitioner · New Bern, NCNPI 1528743036

Payments from drug & device makers

$1,171in general payments, 2019–2025

Across 34 payments — averaging $34.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$341
  • Nxstage Medical, Inc.$225
  • Fresenius USA Marketing, Inc.$209
  • Bayer$84
  • Ardelyx, Inc.$65
  • Amgen$50
  • plus $197 from 8 others

What the payments were for

  • Food & beverage$1,171100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,171 in reported general payments places this provider in the 80th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$76,316
Medicare patients
314
Services billed
3,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuryxiaFerric Citrate62$145,281
VelphoroSucroferric Oxyhydroxide47$138,595
FarxigaDapagliflozin Propanediol64$43,433
JardianceEmpagliflozin50$34,146
VeltassaPatiromer Calcium Sorbitex33$9,020
EliquisApixaban12$8,239
LokelmaSodium Zirconium Cyclosilicate19$6,692
Sevelamer Carbonate28$4,439
Nifedipine ErNifedipine67$1,084
Losartan Potassium82$778
Furosemide85$394
Carvedilol45$381
Gabapentin22$301
Hydralazine Hcl22$261
Calcitriol28$239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$209$138,59547 claims
AstraZenecaFarxiga, Lokelma$341$50,12483 claims
Boehringer IngelheimJardiance$31$34,14650 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →